Kintara Therapeutics Inc Appoints Corporate Finance Veteran Tamara Seymour to Board of Directors


Seymour replaces John Liatos, who will continue in his role as senior vice president of business development for Kintara

Kintara Therapeutics Inc (NASDAQ: KTRA) has announced the appointment of corporate finance veteran Tamara Seymour to its board of directors.

Seymour is replacing John Liatos, who will retain his role as senior vice president of business development for Kintara, the company said.

“We are delighted to welcome Tamara to the Board of Directors, as she brings exceptional experience in the healthcare sector as a accomplished financial and operational executive,” said Kintara CEO Saiid Zarrabian in a statement. communicated.

READ: Kintara Therapeutics says data from interim Phase 2 study of VAL-083 shows potential as a breakthrough treatment option for patients with GBM

“Tamara’s insights and perspectives will be a valuable addition to the Board of Directors and to the entire company as we continue to advance our VAL-083 and REM-001 platform assets. We would like to thank John for his service to the Board of Directors and are delighted to continue working with him as Senior Vice President of Business Development for the company, ”added Zarrabian.

Kintara noted that Seymour has three decades of experience in the biotechnology and life science industries, including 20 years as a chief financial officer. His experience includes finance management, investor relations, managed care and reimbursement, human resources, administration and information technology.

She has raised over $ 250 million in multiple private and public equity and debt financings, including leading an IPO. She is a member of the board of directors and audit committee of Artelo Biosciences Inc (NASDAQ: ARTL), a clinical-stage biopharmaceutical company in California, and former CFO of several private and public companies where she played a role. essential in merger and acquisition activities. .

Her most recent CFO roles included acting CFO of Immunic Inc (NASDAQ: IMUX), a clinical-stage drug development company where she was instrumental in its transition from a private entity. funded by venture capital to a publicly traded company after the merger. company with Vital Therapies Inc.

Seymour was also CFO of molecular diagnostics company Signal Genetics Inc and CFO of Favrille Inc, a clinical stage drug development company.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham


Comments are closed.